Menu
  • The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • Barrow ALA Trial for Recurrent Malignant Gliomas

    This study is being done to find which dose of 5-ALA is the best for seeing recurrent gliomas during surgery. Select patients will take an oral dose of study drug (5-ALA) a few hours before surgery. During the procedure surgeons use a special microscope that sends out blue light onto the tumor tissue where 5-ALA reflects the light causing the abnormal cells to glow in the dark. When there is suspected regrowth of tumor, surrounding tissue can also look like tumor because of prior surgery, treatment with radiation or chemotherapy which cause change in the tissue. Tissue samples taken during surgery will be inspected by a pathologist to confirm whether or not the tumor tissue has recurrent tumor cells. This will help the researchers decide what dose would be best to use in future patients with recurrent disease.

     

    About Barrow Neurological Institute

    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.